Considering that DPP-4 inhibitors have also been shown to have adverse cardiovascular side effects such as sympathetic overactivation, and the induction of heart failure [254,255], further studies must be performed to clarify whether long-term treatment with DPP-4 inhibitors in T2DM patients is a viable therapeutic avenue. Here, DPP4 is linked to heart failure.